Patient Support Services Contact Us



Coherus BioSciences, Inc. is a leading global biologics platform company focused on delivering high-quality biosimilar therapeutics that may expand patient access to life-changing medicines in regulated markets worldwide. In 2018, the U.S. Food and Drug Administration approved Coherus’ biosimilar UDENYCA® (pegfilgrastim-cbqv). Coherus is headquartered in the heart of California’s Silicon Valley and composed of a team of industry veterans with decades of experience pioneering biologics companies.

REDWOOD CITY, Calif. , Aug. 22, 2019 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Nasdaq: CHRS), today announced that effective August 21, 2019 , the compensation committee of the company’s board of directors granted 13 new employees options to purchase an aggregate of 197,000 shares of the
REDWOOD CITY, Calif. , Aug. 21, 2019 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Nasdaq: CHRS), today announced that senior management will present at two upcoming investor healthcare conferences. Management will deliver a company presentation at the Baird 2019 Global Healthcare Conference on
– Company is Profitable and Cash flow Positive from Operations for Second Quarter –  – UDENYCA ® is the Market Leading Pegfilgrastim Biosimilar with Approximately 13% Market Share – REDWOOD CITY, Calif. , Aug. 01, 2019 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc.
REDWOOD CITY, Calif. , July 29, 2019 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus” or “the Company”, Nasdaq: CHRS), today announced that the United States Court of Appeals for the Federal Circuit has affirmed the decision of the United States District Court for the District of Delaware